134 related articles for article (PubMed ID: 30982718)
1. Pretreatment Blood Pressure is a Simple Predictor of Hemorrhagic Infarction after Intravenous Recombinant Tissue Plasminogen Activator (rt-PA) Therapy.
Ohtani R; Nakamura M; Nirengi S; Kawakami O; Togawa J; Doi K; Sainouchi M; Kuwata Y; Takata M; Masuda Y; Matsunari R; Takeda K; Tsukahara T; Sakane N
J Stroke Cerebrovasc Dis; 2019 Jul; 28(7):1979-1986. PubMed ID: 30982718
[TBL] [Abstract][Full Text] [Related]
2. Cerebral Microbleeds are an Independent Predictor of Hemorrhagic Transformation Following Intravenous Alteplase Administration in Acute Ischemic Stroke.
Nagaraja N; Tasneem N; Shaban A; Dandapat S; Ahmed U; Policeni B; Olalde H; Shim H; Samaniego EA; Pieper C; Ortega-Gutierrez S; Leira EC; Adams HP
J Stroke Cerebrovasc Dis; 2018 May; 27(5):1403-1411. PubMed ID: 29398533
[TBL] [Abstract][Full Text] [Related]
3. Computed Tomography Perfusion Derived Blood-Brain Barrier Permeability Does Not Yet Improve Prediction of Hemorrhagic Transformation.
Horsch AD; Bennink E; van Seeters T; Kappelle LJ; van der Graaf Y; Mali WPTM; de Jong HWAM; Velthuis BK; Dankbaar JW;
Cerebrovasc Dis; 2018; 45(1-2):26-32. PubMed ID: 29402765
[TBL] [Abstract][Full Text] [Related]
4. Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry.
Mori M; Naganuma M; Okada Y; Hasegawa Y; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Kario K; Okuda S; Koga M; Minematsu K; Toyoda K
Cerebrovasc Dis; 2012; 34(2):140-6. PubMed ID: 22854333
[TBL] [Abstract][Full Text] [Related]
5. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
Ong CT; Wong YS; Wu CS; Su YH
Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721
[TBL] [Abstract][Full Text] [Related]
6. Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with rivaroxaban.
Ishihara H; Torii H; Imoto H; Oka F; Sadahiro H; Suzuki M
J Stroke Cerebrovasc Dis; 2014; 23(10):e457-e459. PubMed ID: 25280819
[TBL] [Abstract][Full Text] [Related]
7. Combined approach to lysis utilizing eptifibatide and recombinant tissue plasminogen activator in acute ischemic stroke-enhanced regimen stroke trial.
Pancioli AM; Adeoye O; Schmit PA; Khoury J; Levine SR; Tomsick TA; Sucharew H; Brooks CE; Crocco TJ; Gutmann L; Hemmen TM; Kasner SE; Kleindorfer D; Knight WA; Martini S; McKinney JS; Meurer WJ; Meyer BC; Schneider A; Scott PA; Starkman S; Warach S; Broderick JP;
Stroke; 2013 Sep; 44(9):2381-7. PubMed ID: 23887841
[TBL] [Abstract][Full Text] [Related]
8. Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the third international stroke trial.
Whiteley WN; Thompson D; Murray G; Cohen G; Lindley RI; Wardlaw J; Sandercock P;
Stroke; 2014 Apr; 45(4):1000-6. PubMed ID: 24603072
[TBL] [Abstract][Full Text] [Related]
9. Drop of PT Quick percent value is associated with both symptomatic and asymptomatic intracranial hemorrhage in patients treated with rt-PA for acute ischemic stroke.
Alonso A; Dempfle CE; Szabo K; Zohsel K; Hennerici MG
Thromb Res; 2011 Jan; 127(1):65-6. PubMed ID: 20537372
[No Abstract] [Full Text] [Related]
10. A matched comparison of eptifibatide plus rt-PA versus rt-PA alone in acute ischemic stroke.
Adeoye O; Knight WA; Khoury J; Schmit PA; Sucharew H; Broderick JP; Pancioli AM;
J Stroke Cerebrovasc Dis; 2014; 23(5):e313-5. PubMed ID: 24534128
[TBL] [Abstract][Full Text] [Related]
11. Clinical Study of Intravenous, Low-Dose Recombinant Tissue Plasminogen Activator for Acute Cerebral Infarction: Comparison of Treatment within 3 Hours versus 3-4.5 Hours.
Deguchi I; Tanahashi N; Takao M
J Stroke Cerebrovasc Dis; 2018 Apr; 27(4):1033-1040. PubMed ID: 29221968
[TBL] [Abstract][Full Text] [Related]
12. Influence of antiplatelet pre-treatment on the risk of symptomatic intracranial haemorrhage after intravenous thrombolysis.
Bravo Y; Martí-Fàbregas J; Cocho D; Rodríguez-Yáñez M; Castellanos M; de la Ossa NP; Roquer J; Obach V; Maestre J; Martí-Vilalta JL
Cerebrovasc Dis; 2008; 26(2):126-33. PubMed ID: 18560215
[TBL] [Abstract][Full Text] [Related]
13. Importance of leukoaraiosis on CT for tissue plasminogen activator decision making: evaluation of the NINDS rt-PA Stroke Study.
Demchuk AM; Khan F; Hill MD; Barber PA; Silver B; Patel S; Levine SR;
Cerebrovasc Dis; 2008; 26(2):120-5. PubMed ID: 18560214
[TBL] [Abstract][Full Text] [Related]
14. Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator.
Betts KA; Hurley D; Song J; Sajeev G; Guo J; Du EX; Paschoalin M; Wu EQ
J Stroke Cerebrovasc Dis; 2017 Sep; 26(9):1996-2003. PubMed ID: 28689999
[TBL] [Abstract][Full Text] [Related]
15. A model to prevent fibrinolysis in patients with stroke mimics.
Chang J; Teleb M; Yang JP; Alderazi YJ; Chapple K; Frey JL; Restrepo L
J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):839-43. PubMed ID: 21640609
[TBL] [Abstract][Full Text] [Related]
16. The THRIVE score predicts symptomatic intracerebral hemorrhage after intravenous tPA administration in SITS-MOST.
Flint AC; Gupta R; Smith WS; Kamel H; Faigeles BS; Cullen SP; Rao VA; Bath PM; Wahlgren N; Ahmed N; Donnan GA;
Int J Stroke; 2014 Aug; 9(6):705-10. PubMed ID: 25042855
[TBL] [Abstract][Full Text] [Related]
17. Older age does not increase risk of hemorrhagic complications after intravenous and/or intra-arterial thrombolysis for acute stroke.
Pundik S; McWilliams-Dunnigan L; Blackham KL; Kirchner HL; Sundararajan S; Sunshine JL; Tarr RW; Selman WR; Landis DM; Suarez JI
J Stroke Cerebrovasc Dis; 2008 Sep; 17(5):266-72. PubMed ID: 18755405
[TBL] [Abstract][Full Text] [Related]
18. Clinical Predictors of Stroke Mimics in Patients Treated with Recombinant Tissue Plasminogen Activator according to a Normal Multimodal Computed Tomography Imaging.
Olindo S; Chardonnet M; Renou P; Coignion C; Debruxelles S; Poli M; Sagnier S; Rouanet F; Sibon I
J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):454-459. PubMed ID: 29128327
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment blood-brain barrier damage and post-treatment intracranial hemorrhage in patients receiving intravenous tissue-type plasminogen activator.
Leigh R; Jen SS; Hillis AE; Krakauer JW; Barker PB;
Stroke; 2014 Jul; 45(7):2030-5. PubMed ID: 24876245
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of Stroke Diagnosis in Telestroke-Guided Tissue Plasminogen Activator Patients.
Agrawal K; Raman R; Ernstrom K; Claycomb RJ; Meyer DM; Hemmen TM; Modir RF; Kachhi P; Meyer BC
J Stroke Cerebrovasc Dis; 2016 Dec; 25(12):2942-2946. PubMed ID: 27599906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
